Skip to main content

Table 1 Baseline characteristics of patients suspected for FH

From: Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania

Characteristics Patients suspected for FH
Total Male Female P
N 61 22 39 0.001
Age - yo (mean±SD) 48.4 ± 12.5 46.1 ± 1 49.7 ±1 0.4
Smoker n (%) 18 (29.5%) 12 (54.5%) 6 (15.4%) 0.001*
High blood pressure n (%) 31 (50.8%) 13 (59.1%) 18 (46.2%) 0.3
CHD history n (%) 28 (21.3%) 6 (27.3%) 22 (17.9%) 0.5
PAD history n (%) 10 (14.8%) 3 (13.6%) 7 (15.4%) 0.5
CHD+PAD history n (%) 11 (23%) 5 (22.7%) 6 (23.1%) 0.5
Obesity n (%) 36.1% 8 (36.4%) 14 (35.9%) 0.9
Type 2 diabetes n (%) 8 (13.1%) 4 (18.2%) 4 (10.3%) 0.4
Physical inactivity n (%) 30 (49.2%) 14 (63.6%) 16 (41%) 0.09
TC mg/dL (median±IQR) 315 ± 56 313.5 ± 41 315 ±60 0.7
LDL-C mg/dL (mean±SD) 254.2 ± 53 257 ±63 252.5± 47 0.8
HDL-C mg/dL (median± QR) 45.8 ±18 44 ±19 46 ±18 0.6
TG mg/dL (mean±SD) 174.4 ± 92 163.7± 90 180.5± 94 0.6
Uric acid mg/dL (mean±SD) 5.79 ± 1.22 6.2 ±1.1 5.5 ±1.2 0.02*
hsCRP mg/L (mean±SD) 5.85 ± 2.29 6.3 ±2.5 5.9± 2 0.5
ECG changes n (%) 25 (41%) 11 (50) 14 (35.9) 0.3
LV wall motion abnormalities n (%) 25 (41%) 11 (50) 14 (35.9) 0.1
ABI (mean±SD) 0.96±0.93 0.84±0.09 1.01±1.4 0.8
cIMT mm (mean±SD) 0.95±0.33 1.02±0.34 0.9±0.32 0.2
Lipid-Lowering Agents     0.3
Statin n (%) 22 (36.1%) 7(39.8%) 15(38.5%)  
Statin + ezetimibe n (%) 18 (29.5%) 11 (50%) 7 (17.9%)  
Statin + fenofibrate n (%) 8 (13.1%) 3 (13.6%) 5 (12.8%)  
Statin + fenofibrate + ezetimibe n (%) 13 (21.3%) 1 (4.5%) 12 (30.8%)  
Adverse effects n (%) 3% 1% 2%  
  1. Legend: CHD coronary heart disease, PAD Peripheral arterial disease, TC Total cholesterol, LDL-C low density cholesterol lipoprotein, HDL-C high density cholesterol lipoprotein, TG triglycerides, hsCRP high-sensitivity C-reactive protein, ECG electrocardiogram, LV-left ventricular, ABI ankle-brachial index, cIMT carotid intima-media thickness
  2. *P< 0.05